Authors' Reply: Hybrid Approach for Atrial Fibrillation Ablation: the Jury is Still Out




Citation:Arrhythmia & Electrophysiology Review 2018;7(1):65–6.

Open access:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Dear Sir,

We thank Drs Giannopoulos and Deftereos for showing interest in our work.1 They wonder whether a true difference might exist between hybrid and epicardial ablation alone that may have been masked by our combining the results from retrospective observational studies with those from randomised trials.

A fine balance needs to be struck for this type of analysis. On one hand, adopting narrow inclusion criteria will ensure that the studies within each group share very similar designs, interventions and populations, minimising the chance of dilution of a genuine difference between groups. On the other hand, using broad inclusion criteria will increase statistical power by including a larger number of studies. Previous work exploring outcomes following atrial fibrillation ablation has shown that results from observational studies match those from randomised trials and can strengthen the power of a meta-analysis.2 We have tried to reconcile this dilemma by presenting our primary outcome first using a broad inclusion strategy and subsequently by verifying this in sensitivity analyses designed to reduce heterogeneity. Each sensitivity analysis that was performed confirmed the initial conclusion that there was no detectable advantage associated with routine hybrid ablation.

Seven randomised trials of epicardial ablation alone were included, and the pooled estimate of 12-month survival free from atrial arrhythmias without antiarrhythmic drugs in these studies was 70.7 %, similar to the result (71.5 %) when all studies were included. However, it is notable that major complications were reported to occur in 31 of the 602 (5.1 %) patients included in randomised trials, considerably more than the pooled estimate of 2.9 % when all studies were included, suggesting that under-reporting of complications may have been present among non-randomised studies. We were unable to compare epicardial-alone with hybrid ablation in this sensitivity analysis as no randomised trials of hybrid ablation could be found that met our inclusion criteria.

Giannopoulos and Deftereos enquire about the definition used for hybrid ablation. We used the term to include all studies in which a combination of epicardial and endocardial ablation was used routinely, either simultaneously or as a staged procedure. Studies in which supplementary endocardial ablation was used only in cases of recurrent arrhythmia were not included in this group. Despite theoretical concerns that simultaneous hybrid ablation may be less effective, the single study we are aware of that has compared staged with simultaneous hybrid ablation showed no difference in success rates between these strategies.3 We agree that the confirmation of electrical isolation could potentially be less reliable using a simultaneous hybrid approach. Interestingly, although some studies reported performing epicardial ablation without verification of conduction block, metaregression did not identify this as a significant predictor of arrhythmia recurrence.

The readers’ third point addresses the usage of ambulatory monitoring to detect recurrent arrhythmias. We fully appreciate that a higher prevalence of extended ambulatory monitoring is more likely to correctly identify treatment failure. In view of this, we performed a sensitivity analysis including only studies in which patients underwent at least 1 week of ambulatory monitoring in total over the follow-up period. Seventy-five per cent of patients in the epicardial-alone group remained free from atrial arrhythmias at 12 months compared to 61 % of patients in the hybrid group, once again failing to find a benefit for routine hybrid ablation.

In summary, multiple sensitivity analyses aimed at decreasing heterogeneity within the treatment groups supported our initial results, leading us to conclude that evidence supporting a role for routine hybrid ablation is lacking.

Charles M Pearman, Liverpool Heart and Chest Hospital, Liverpool and Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
Dhiraj Gupta, Liverpool Heart and Chest Hospital, Liverpool, UK


  1. Pearman CM, Poon SS, Bonnett LJ, et al. Minimally invasive epicardial surgical ablation alone versus hybrid ablation for atrial fibrillation: a systematic review and meta-analysis. Arrhythm Electrophysiol Rev 2017;6(4):202–9.
    Crossref | PubMed
  2. Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol Dec 2009;62:1253–60.e1254.
    Crossref | PubMed
  3. Richardson TD, Shoemaker MB, Whalen SP, et al. Staged versus simultaneous thoracoscopic hybrid ablation for persistent atrial fibrillation does not affect time to recurrence of atrial arrhythmia. J Cardiovasc Electrophysiol 2016;27:428–34.
    Crossref | PubMed